AMLX vs EXAS · $561.6M cap vs rev $2.76B
Amylyx Pharmaceuticals Inc (AMLX) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
AMLX currently screens at market cap $561.6M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the AMLX and EXAS stock pages for the full models.
Not investment advice.